0001209191-23-052389.txt : 20231006
0001209191-23-052389.hdr.sgml : 20231006
20231006215910
ACCESSION NUMBER: 0001209191-23-052389
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231005
FILED AS OF DATE: 20231006
DATE AS OF CHANGE: 20231006
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DAVIS STEPHEN
CENTRAL INDEX KEY: 0001131146
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 231315313
MAIL ADDRESS:
STREET 1: ACADIA PHARMACEUTICALS INC.
STREET 2: 12830 EL CAMINO REAL, SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12830 EL CAMINO REAL
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 12830 EL CAMINO REAL
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-05
0
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001131146
DAVIS STEPHEN
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
SAN DIEGO
CA
92130
1
1
0
0
CEO
0
Common Stock
2023-10-05
4
M
0
103999
A
140694
D
Common Stock
2023-10-06
4
S
0
51563
21.96
D
89131
D
Restricted Stock Units
2023-10-06
4
M
0
103999
0.00
D
Common Stock
103999
173332
D
Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
Includes 1,594 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on May 15, 2023.
The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
/s/ Austin D. Kim, Attorney-in-Fact
2023-10-06